The global Immunohistochemistry (IHC) Market is projected to grow steadily from USD 3.31 billion in 2024 to USD 3.55 billion in 2025, and further to USD 5.14 billion by 2030, registering a CAGR of 7.6% during the forecast period.
This robust growth is primarily driven by the rising global burden of cancer, fueling demand for accurate and efficient diagnostic solutions. Immunohistochemistry (IHC) testing remains a cornerstone in cancer diagnosis, biomarker detection, and personalized medicine, offering clinicians essential insights for targeted treatment strategies.
🔗 Download PDF Brochure
📘 Browse 666 Tables, 63 Figures, and 490 Pages of In-depth Market Analysis
Market Drivers: Growing Cancer Incidence and Diagnostic Innovation
The surge in cancer prevalence worldwide has accelerated the adoption of IHC tools, with hospitals, diagnostic laboratories, and research institutions investing heavily in automated, high-accuracy testing systems.
Major manufacturers are focusing on:
- Developing next-generation antibodies and reagents
- Launching automated staining and detection platforms
- Enhancing workflow automation for pathology labs
The increasing integration of personalized medicine—which tailors treatment based on individual molecular and protein markers—further amplifies the market potential for IHC solutions.
Market Segmentation by Offering
The IHC market is segmented by antibodies, reagents, kits, equipment, and software.
Among these, IHC kits are expected to witness the fastest growth from 2025 to 2030.
Why Kits Dominate:
- Growing adoption of ready-to-use, standardized diagnostic kits
- Reduction in manual processing time and workflow errors
- Consistent, reproducible results critical for clinical and academic applications
- Preference among high-volume laboratories and hospitals for comprehensive, integrated solutions
These factors are collectively driving demand for closed-system IHC kits, improving laboratory efficiency and diagnostic precision.
Market Segmentation by End User
Based on end user, the market includes:
- Hospitals & Diagnostic Laboratories
- Academic Institutes & Contract Research Organizations (CROs)
- Other End Users
The hospitals & diagnostic laboratories segment accounted for the largest share in 2024.
The expansion is driven by:
- IHC’s critical role in cancer, infectious disease, and autoimmune disorder diagnostics
- Increasing demand for in-house diagnostic capabilities to improve turnaround times
- Adoption of protein biomarker identification tools guiding targeted cancer therapies
As cancer cases continue to climb globally—supported by WHO projections—the need for reliable, rapid, and cost-effective diagnostic testing will continue to strengthen the dominance of this segment.
Regional Insights: Asia Pacific Leads Global Growth
The Asia Pacific region emerged as the leading market in 2024, supported by rapid healthcare infrastructure expansion and a surge in chronic disease incidence.
Key Growth Factors:
- Government healthcare investments: China’s Healthy China 2030 and India’s Ayushman Bharat initiatives
- Rising cancer prevalence across China, India, and Southeast Asia
- Expansion of private diagnostic chains in India and Indonesia
- Growing presence of CROs supporting global clinical trials utilizing IHC assays
- Medical tourism hubs like Singapore and Thailand driving demand for advanced diagnostics
These combined factors make Asia Pacific a hub for innovation, accessibility, and adoption of IHC technologies.
Key Market Players
The immunohistochemistry market is moderately consolidated, featuring global and regional leaders such as:
F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), Becton, Dickinson and Company (US), Takara Bio Inc. (Japan), PHC Holdings Corporation (Japan), Enzo Biochem Inc. (US), Sino Biological, Inc. (China), OriGene Technologies, Inc. (US), and others.
Company Insights
F. Hoffmann-La Roche Ltd (Switzerland)
Roche maintains a dominant position in the IHC market with its BenchMark and OptiView systems.
Key innovations include:
- BenchMark ULTRA PLUS System (2022)
- VENTANA ALK (D5F3) CDx Assay (2021)
The company’s focus on next-generation antibodies and automation reinforces its global diagnostic leadership.
Danaher Corporation (US)
Through its subsidiary Leica Biosystems, Danaher provides cutting-edge IHC and anatomical pathology solutions.
The firm invested USD 1.5 billion in R&D (2023) and recently partnered with Navinci (Sweden) in 2024 to advance automated in situ assays for cancer research.
Agilent Technologies, Inc. (US)
Agilent’s Pathology Solutions division focuses on cancer diagnostics and genomics.
The company is expanding its global footprint through:
- A 2022 Center of Excellence in India
- Collaborations with Incyte (US) (2024) and Akoya Biosciences (US) (2023)
These initiatives strengthen its innovation pipeline and market reach in both developed and emerging economies.
Conclusion: IHC Market Poised for Robust Growth
The immunohistochemistry market is on a transformative trajectory driven by:
- Growing cancer cases
- Expanding personalized medicine applications
- Advances in automation and assay development
- Rising adoption across emerging healthcare economies
With major players investing in AI-assisted pathology, automated staining systems, and multiplex diagnostics, the IHC industry is set to redefine the standards for precision oncology and molecular diagnostics by 2030.
